Exploiting cancer cell vulnerabilities to develop a combination therapy for Ras-driven tumors

Ras-driven tumors are often refractory to conventional therapies. Here we identify a promising targeted therapeutic strategy for two Ras-driven cancers: Nf1-deficient malignancies and KRas/p53-mutant lung cancer. We show that agents that enhance proteotoxic stress, including the HSP90 inhibitor IPI-...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: De Raedt, Thomas, Walton, Zandra, Yecies, Jessica L., Li, Danan, Chen, Yimei, Malone, Clare F., Maertens, Ophelia, Jeong, Seung Min, Bronson, Roderick T., Lebleu, Valerie, Kalluri, Raghu, Normant, Emmanuel, Haigis, Marcia C., Manning, Brendan D., Wong, Kwok-Kin, Macleod, Kay F, Cichowski, Karen
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3233475/
https://ncbi.nlm.nih.gov/pubmed/21907929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2011.08.014
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki